Diadema Partners LP Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Diadema Partners LP bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,719 shares of the specialty pharmaceutical company's stock, valued at approximately $1,813,000. Jazz Pharmaceuticals accounts for approximately 0.8% of Diadema Partners LP's holdings, making the stock its 28th biggest position.

Other large investors have also made changes to their positions in the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $25,000. Quadrant Capital Group LLC lifted its position in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Allianz SE purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at $29,000. Finally, Jones Financial Companies Lllp raised its holdings in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $1.82 during trading on Friday, reaching $110.80. 896,340 shares of the stock were exchanged, compared to its average volume of 798,495. The stock has a 50 day simple moving average of $124.64 and a 200-day simple moving average of $122.31. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $6.73 billion, a P/E ratio of 15.61, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research reports. Morgan Stanley reaffirmed an "overweight" rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $187.71.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Patricia Carr sold 4,813 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares of the company's stock, valued at $1,189,587.54. This trade represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,736 shares of company stock worth $4,023,305. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.